Literature DB >> 16288052

Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.

Antimo Migliaccio1, Marina Di Domenico, Gabriella Castoria, Merlin Nanayakkara, Maria Lombardi, Antonietta de Falco, Antonio Bilancio, Lilian Varricchio, Alessandra Ciociola, Ferdinando Auricchio.   

Abstract

Under conditions of short-term hormone deprivation, epidermal growth factor (EGF) induces DNA synthesis, cytoskeletal changes, and Src activation in MCF-7 and LNCaP cells. These effects are drastically inhibited by pure estradiol or androgen antagonists, implicating a role of the steroid receptors in these findings. Interestingly, EGF triggers rapid association of Src with androgen receptor (AR) and estradiol receptor alpha (ERalpha) in MCF-7 cells or ERbeta in LNCaP cells. Here, we show that, through EGF receptor (EGFR) and erb-B2, EGF induces tyrosine phosphorylation of ER preassociated with AR, thereby triggering the assembly of ER/AR with Src and EGFR. Remarkably, experiments in Cos cells show that this complex stimulates EGF-triggered EGFR tyrosine phosphorylation. In turn, estradiol and androgen antagonists, through the Src-associated receptors, prevent Src activation by EGF and heavily reduce EGFR tyrosine phosphorylation and the subsequent multiple effects, including DNA synthesis and cytoskeletal changes in MCF-7 cells. In addition, knockdown of ERalpha or AR gene by small interfering RNA (siRNA) almost abolishes EGFR tyrosine phosphorylation and DNA synthesis in EGF-treated MCF-7 cells. The present findings reveal that steroid receptors have a key role in EGF signaling. EGFR tyrosine phosphorylation, depending on Src, is a part of this mechanism. Understanding of EGF-triggered growth and invasiveness of mammary and prostate cancer cells expressing steroid receptors is enhanced by this report, which reveals novel aspects of steroid receptor action.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16288052     DOI: 10.1158/0008-5472.CAN-05-0912

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  62 in total

1.  PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase.

Authors:  Murielle Glondu-Lassis; Mathilde Dromard; Magali Lacroix-Triki; Philippe Nirdé; Carole Puech; Dora Knani; Dany Chalbos; Gilles Freiss
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

Review 2.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

Review 3.  Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.

Authors:  Jennifer R Ribeiro; Richard N Freiman
Journal:  J Steroid Biochem Mol Biol       Date:  2014-02-22       Impact factor: 4.292

Review 4.  Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis.

Authors:  Ami Patel; Harika Sabbineni; Andrea Clarke; Payaningal R Somanath
Journal:  Life Sci       Date:  2016-05-28       Impact factor: 5.037

5.  Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.

Authors:  Andrew Ciupek; Yassine Rechoum; Guowei Gu; Luca Gelsomino; Amanda R Beyer; Lauren Brusco; Kyle R Covington; Anna Tsimelzon; Suzanne A W Fuqua
Journal:  Breast Cancer Res Treat       Date:  2015-10-20       Impact factor: 4.872

6.  Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor.

Authors:  Yun Teng; Lacey M Litchfield; Margarita M Ivanova; Russell A Prough; Barbara J Clark; Carolyn M Klinge
Journal:  Mol Cell Endocrinol       Date:  2014-05-17       Impact factor: 4.102

7.  Research resource: EPSLiM: ensemble predictor for short linear motifs in nuclear hormone receptors.

Authors:  Ran Xue; Mikhail N Zakharov; Yu Xia; Shalender Bhasin; James C Costello; Ravi Jasuja
Journal:  Mol Endocrinol       Date:  2014-03-28

Review 8.  PELP1: A novel therapeutic target for hormonal cancers.

Authors:  Dimple Chakravarty; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  IUBMB Life       Date:  2010-03       Impact factor: 3.885

Review 9.  Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways.

Authors:  Emily M Fox; Josefa Andrade; Margaret A Shupnik
Journal:  Steroids       Date:  2008-11-05       Impact factor: 2.668

10.  Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib.

Authors:  Giulia Pinton; Warren Thomas; Paolo Bellini; Arcangela Gabriella Manente; Roberto E Favoni; Brian J Harvey; Luciano Mutti; Laura Moro
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.